Exemestane (Aromasin) for Estrogen Management — Testosterone & Androgens
Steroidal (suicidal) aromatase inhibitor that permanently inactivates aromatase, used off-label for estradiol control during TRT.
Overview
Exemestane is a third-generation steroidal aromatase inhibitor that acts as a false substrate for the aromatase enzyme (CYP19A1). Unlike anastrozole and letrozole, which are competitive reversible inhibitors, exemestane binds irreversibly to aromatase, causing permanent inactivation — hence the term 'suicidal inhibitor.' New enzyme synthesis is required to restore aromatase activity, providing a more sustained effect. This mechanism is preferred by some clinicians for TRT patients because it may have a less negative impact on lipid profiles compared to non-steroidal AIs, and its androgenic metabolite 17-hydroexemestane has mild androgenic activity. Exemestane is FDA-approved for adjuvant treatment of estrogen receptor-positive breast cancer in postmenopausal women after 2-3 years of tamoxifen therapy. In the TRT setting, typical doses range from 12.5 mg twice weekly to 25 mg twice weekly, titrated to estradiol levels. Like all aromatase inhibitors, excessive use can lead to detrimental effects on bone density, lipids, and overall well-being.
Indications
- FDA-approved: Adjuvant treatment of ER-positive breast cancer after tamoxifen in postmenopausal women
- FDA-approved: Advanced breast cancer progressing on tamoxifen
- Off-label: Estradiol management during TRT
- Off-label: Gynecomastia prevention
- Off-label: Male infertility (improving T:E2 ratio)
Mechanism of Action
Exemestane's steroidal structure mimics the natural substrate androstenedione, allowing it to bind to the aromatase active site
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Exemestane | 12.5 mg | Twice weekly | Starting dose for TRT estrogen management |
| Exemestane | 12.5 mg | Every other day | Moderate dosing for persistent E2 elevation |
| Exemestane | 25 mg | Twice weekly | Higher dose for refractory cases |
| Exemestane | 25 mg | Once daily | FDA-approved breast cancer dosing |
Evidence Grade
GRADE B
Safety & Contraindications
- Irreversible mechanism — effects persist until new aromatase is synthesized (2-3 days for recovery)
- May decrease bone mineral density with chronic use, though potentially less than non-steroidal AIs
- Hot flashes, fatigue, arthralgia, and insomnia reported
- Lipid effects may be less pronounced than anastrozole due to mild androgenic metabolite
- Hepatotoxicity rare but monitor LFTs
- Avoid in pregnancy — Category X